Shabanpour Yaser, Sajjadi Sharareh, Behmard Esmaeil, Abdolmaleki Parviz, Keihan Amir Homayoun
Molecular Biology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Department of Biology, Roudehen Branch, Islamic Azad University, Roudehen, Iran.
Front Mol Biosci. 2022 Aug 15;9:927373. doi: 10.3389/fmolb.2022.927373. eCollection 2022.
The human immunodeficiency virus type 1 protease (HIV-1 PR) is an important enzyme in the life cycle of the HIV virus. It cleaves inactive pre-proteins of the virus and changes them into active proteins. Darunavir (DRV) suppresses the wild-type HIV-1 PR (WT-Pr) activity but cannot inhibit some mutant resistant forms (MUT-Pr). Increasing knowledge about the resistance mechanism can be helpful for designing more effective inhibitors. In this study, the mechanism of resistance of a highly MUT-Pr strain against DRV was investigated. For this purpose, complexes of DRV with WT-Pr (WT-Pr-D) and MUT-Pr (MUT-Pr-D) were studied by all-atom molecular dynamics simulation in order to extract the dynamic and energetic properties. Our data revealed that mutations increased the flap-tip flexibility due to the reduction of the flap-flap hydrophobic interactions. So, the protease's conformation changed from a closed state to a semi-open state that can facilitate the disjunction of DRV from the active site. On the other hand, energy analysis limited to the final basins of the energy landscape indicated that the entropy of binding of DRV to MUT-Pr was more favorable than that of WT-Pr. However, the enthalpy penalty overcomes it and makes binding more unfavorable relative to the WT-Pr. The unfavorable interaction of DRV with R8, I50, I84, D25', and A28' residues in MUT-Pr-D relative to WT-Pr-D is the reason for this enthalpy penalty. Thus, mutations drive resistance to DRV. The hydrogen bond analysis showed that compared with WT-Pr, the hydrogen bonds between DRV and the active-site residues of MUT-Pr were disrupted.
人类免疫缺陷病毒1型蛋白酶(HIV-1 PR)是HIV病毒生命周期中的一种重要酶。它切割病毒的无活性前体蛋白并将其转变为活性蛋白。达芦那韦(DRV)可抑制野生型HIV-1 PR(WT-Pr)的活性,但无法抑制某些突变抗性形式(MUT-Pr)。增加对耐药机制的了解有助于设计更有效的抑制剂。在本研究中,对一种高度耐药的MUT-Pr毒株对DRV的耐药机制进行了研究。为此,通过全原子分子动力学模拟研究了DRV与WT-Pr(WT-Pr-D)和MUT-Pr(MUT-Pr-D)的复合物,以提取其动力学和能量特性。我们的数据显示,由于瓣叶间疏水相互作用的减少,突变增加了瓣叶尖端的灵活性。因此,蛋白酶的构象从闭合状态转变为半开放状态,这有助于DRV从活性位点解离。另一方面,仅限于能量景观最终盆地的能量分析表明,DRV与MUT-Pr结合的熵比与WT-Pr结合的熵更有利。然而,焓罚克服了这一点,使得相对于WT-Pr,结合更不利。DRV与MUT-Pr-D中R8、I50、I84、D25'和A28'残基相对于WT-Pr-D的不利相互作用是这种焓罚的原因。因此,突变导致对DRV的耐药性。氢键分析表明,与WT-Pr相比,DRV与MUT-Pr活性位点残基之间的氢键被破坏。